QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.103.054429v1 307/3/1227    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gengo, P. J. Articles by Chang, K.-J. Search for Related Content PubMed PubMed Citation Articles by Gengo, P. J. Articles by Chang, K.-J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ALFENTANIL CARBON DIOXIDE OXYGEN

NEUROPHARMACOLOGY

DPI-3290 [(+)-3-((-R)--((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. II. A Mixed Opioid Agonist with Potent Antinociceptive Activity and Limited Effects on Respiratory Function

Ardent Research Laboratories, Ardent Pharmaceuticals, Inc., Durham, North Carolina

Received May 13, 2003; accepted August 21, 2003.

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
Allyl-2,5-dimethyl-1-piperazines have been of interest as analgesic agents for the management of moderate-to-severe pain. In this study, we compared the antinociceptive properties and respiratory depressant activity of one such agent, (+)-3-((-R)--((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide (DPI-3290), with those of established narcotic analgesics, morphine and fentanyl. Intravenous administration of DPI-3290 in conscious laboratory rats increased antinociception in a dose-dependent manner with a corresponding ED₅₀ value of 0.05 ± 0.0072 mg/kg. Simultaneous measurement of arterial blood gas in animals treated with DPI-3290 demonstrated dose-dependent increases in pCO₂ with an ED₅₀ value of 0.91 ± 0.22 mg/kg. In comparison, morphine and fentanyl increased antinociception in rats with ED₅₀ values of 2.01 ± 0.0005 and 0.0034 ± 0.00024 mg/kg, respectively, and the ED₅₀ value for morphine-induced changes in pCO₂ was 4.23 ± 0.72 mg/kg, whereas the ED₅₀ value for fentanyl-induced changes in pCO₂ was 0.0127 ± 0.0035 mg/kg. A separate series of experiments were designed to examine the effects of DPI-3290 on µ-opioid receptor induced antinociception and hypercapnia. Intravenous bolus doses of DPI-3290 that ranged from 0.2 to 1.0 mg/kg had no effect on antinociception mediated by alfentanil (2 µg/kg/min i.v.) but reduced hypercapnia by approximately 50%. Results from these studies demonstrate the equivalent antinociceptive efficacy of DPI-3290, morphine, and fentanyl but dramatic differences in the hypercapnia that antinociceptive doses of these drugs produce. When measured simultaneously, DPI-3290 had an 18.2-fold difference in the ratio comparing the ED₅₀ value for antinociception with the ED₅₀ value for changes in pCO₂; this ratio was 2.1 for morphine and 3.7 for fentanyl. Furthermore, DPI-3290 reduced the alfentanil-mediated hypercapnia without any effect on antinociception. Together, the balanced opioid agonist activity of DPI-3290 may provide a means of powerful analgesia while mitigating the µ-opioid receptor-mediated hypercapnia.

Despite numerous efforts to develop analgesics with improved safety profiles, morphine and fentanyl remain the most widely used narcotic analgesics. Both morphine and fentanyl elicit their pharmacological action by selectively binding to and activating the µ-subtype of the opioid receptor (McGilliard and Takemori, 1978; Chang, 1984). Recently, the analgesic activity of several nonpeptide -opioid receptor agonists has been described (Chang et al., 1993), and there is experimental evidence to support the potential clinical advantages of a compound with combined µ- and -opioid receptor agonist activities (O'Neill et al., 1997). In studies with laboratory rats, additive analgesic actions were measured when fentanyl was administered in combination with the -opioid receptor agonist BW373U86. Not only was there additive analgesic activity in these studies but also coadministration was shown to diminish fentanyl-induced muscle rigidity (straub tail) and attenuate the BW373U86-mediated seizures. Other investigators have demonstrated that prolonged coadministration of morphine and BW373U86 attenuated the development and expression of morphine-induced dependence and tolerance in rats (Lee et al., 1993). Perhaps most importantly, it has been reported that alfentanil-mediated antinociception was not altered by coadministration with BW373U86, and in these studies the alfentanil-mediated respiratory depression was significantly attenuated (Su et al., 1998). Together, these data may suggest that a compound with mixed µ- and -opioid receptor agonist activity may have utility in achieving a similar, or even a greater degree of analgesia and fewer adverse effects when compared with fentanyl or morphine.

DPI-3290 (DPI-3290 is currently being codeveloped with Organon Corporation as Org 41793) was designed and synthesized to act at multiple opioid receptors. We have previously described the nanomolar binding affinity and comparable potency of DPI-3290 to inhibit contractions in electrically stimulated smooth muscle isolated from laboratory animals (Gengo et al., 2003). These actions are consistent with the compounds mixed opioid agoinst properties. We herein describe the in vivo pharmacological actions of the mixed - and µ-opioid receptor agonist DPI-3290 and its subsequent antinociceptive and respiratory effects in laboratory rats.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Arterial Blood Gas and Antinociceptive Studies. Male albino Wistar Hannover rats (Harlan, Madison, WI) weighing 200 to 300 g were anesthetized with 2% isoflurane in a 30% O₂ and 70% N₂O vehicle. Under aseptic conditions, the femoral artery and external jugular vein were isolated and a cannula consisting of Silastic tubing was introduced into the lumen of vessel. The cannulas were anchored with a silk suture, and the incisions were closed with proline. Anesthetic gases were removed, and the rats were allowed to recover in a plastic restrainer for 60 min before administration of test compound and simultaneous measurement of arterial blood gasses and antinociceptive responses.

After intravenous administration of test article, arterial blood was drawn into a syringe with heparin from the femoral artery catheter. The volume of blood taken was 0.15 ml. The syringe was capped and the blood was analyzed immediately (pH/gas analyzer synthesis 25 model; Instrumentation Laboratory, Lexington MA). Caution was taken to avoid exposing the arterial blood sample to atmospheric air. The blood exposed to atmospheric air at the tip of the syringe was expelled before blood gas determinations.

The antinociceptive assay used in these studies was the standard tail-pinch test described previously (Wong, 1992; Le Bars et al., 2001). Briefly, the test was performed with the rat in a Plexiglas restrainer and pressure from an artery clamp was placed on the tail (1 inch from the tip). The clamp remained in place until an escape response occurred (i.e., tail-flick or vocalization) or a maximum time of 20 s had elapsed. The escape response latency was recorded by means of a stopwatch.

Data were converted from the latency response time or unit into a percent maximal possible effect (MPE) score as described below.

Alfentanil Infusion Studies. Male albino Wistar Hannover rats (HDS) weighing 200 to 300 g were anesthetized with 2% isoflurane in a 30% O₂ and 70% N₂O vehicle. A cannula consisting of Silastic tubing was introduced into the lumen of the femoral artery and two others introduced into the lumen of each external jugular vein. The cannulas were anchored to the vessel with a silk suture and the incisions were closed with proline. Anesthetic gases were removed, and rats were allowed to recover in a plastic restrainer for 60 min before continuous intravenous infusion (2 µg/kg) with alfentanil. Alfentanil-mediated changes in pCO₂ and MPE were allowed to stabilize before coadministration of intravenous DPI-3290. Simultaneous measurement of arterial blood gasses and antinociceptive responses were measured during the 60 min alfentanil infusion and then for the 30 min that followed.

Sources of Drugs. Alfenta (alfentanil HCl) was purchased from Taylor Pharmaceuticals (Decatur, IL). Morphine, fentanyl, and all other chemicals were reagent grade and purchased from Sigma-Aldrich (St. Louis, MO). DPI-3290 was synthesized at Ardent Research Laboratories and Burroughs Wellcome Co. (Research Triangle Park, NC) using standard protocols.

Calculations and Statistics. Pharmacological data were analyzed by linear regression of the linear portion of the dose-response curves to determine the EC₅₀ value using the computer program Prism (GraphPad Software Inc., San Diego, CA). The ED₅₀ values and S.E.M. were calculated and represent the curve fit.

	Results

Top Abstract Materials and Methods Results Discussion References

 
To compare and differentiate the actions of DPI-3290 with morphine and fentanyl, studies were designed to simultaneously measure each compounds antinociceptive properties and respiratory depressant activity in conscious laboratory rats. When DPI-3290 was administered intravenously to conscious rats the most striking effect was a dose-related increase in antinociception. The ED₅₀ value for DPI-3290-mediated antinociception was 0.05 ± 0.0072 mg/kg. In addition, this compound also produced an increase in pCO₂, but changes in pCO₂ resulted at markedly higher doses in relationship to those that elicited antinociception, especially compared with morphine or fentanyl. For example, in conscious rats, the ED₅₀ value for hypercapnia mediated by DPI-3290 was 0.91 ± 0.0072, a dose that was 18.2-fold higher than its ED₅₀ value for antinociception. In comparison, the ED₅₀ value for morphine and fentanyl-mediated antinociception in conscious rats was 2.01 ± 0.0005 and 0.0034 ± 0.0002, respectively; doses that were only 2.1-fold lower than the ED₅₀ value for hypercapnia with morphine and 3.7-fold lower for the ED₅₀ value for hypercapnia with fentanyl (Table 1).

Gengo et al. (2003) have demonstrated that DPI-3290 binds selectively and with high affinity to -, µ-, and -opioid receptors. These investigators also reported greater potency at µ-opioid receptors when DPI-3290 was compared with morphine and similar activity compared with fentanyl. As shown in Figs. 1, 2, and 3, the efficacy of DPI-3290-mediated effects on tail-pinch latency (MPE) was similar compared with morphine or fentanyl in that full antinociceptive action was measured in rats treated with DPI-3290, morphine, or fentanyl. Also illustrated in Figs. 1, 2, 3 are the concomitant changes in pCO₂, pO₂, and pH that were mediated by DPI-3290, morphine, and fentanyl. As would be expected, the opioid-mediated antinociceptive actions of these compounds were linked to changes in pCO₂, pO₂, and pH, but with differing potencies when standardized to their antinociceptive activity. For example, at the maximum doses that were tolerated by rats in these studies with DPI-3290, morphine, and fentanyl, the percentage of increase in pCO₂ elicited by DPI-3290 was 78.6 ± 5.9%, whereas the increase elicited by morphine was 72.8 ± 8.8% and that by fentanyl was 112.3 ± 13.9%. However, even as the changes in pCO₂ mediated by maximal tolerated doses of DPI-3290, morphine, and fentanyl seem similar, they are markedly different compared with their antinociceptive activity. The 78.6 ± 5.9% increase in pCO₂ mediated by DPI-3290 was measured at a dose that was 40 times its ED₅₀ value for antinociception. Similar changes in pCO₂ were elicited by maximal tolerated doses of morphine but at a dose that was only 4 times its ED₅₀ value for antinociception and by fentanyl, which was 12 times its ED₅₀ value for antinociception.

View larger version (35K): [in this window] [in a new window]   Fig. 1. Time course for the changes in MPE, pCO2,pO2, and pH induced by intravenous administration of DPI-3290 at the doses indicated. At the time points outlined in the figure, tail-pinch testing and arterial blood samples were collected and analyzed as described under Materials and Methods.

View larger version (27K): [in this window] [in a new window]   Fig. 2. Time course for the changes in MPE, pCO2,pO2, and pH induced by intravenous administration of morphine at the doses indicated. At the time points outlined in the figure, tail-pinch testing, and arterial blood samples were collected and analyzed as described under Materials and Methods.

View larger version (31K): [in this window] [in a new window]   Fig. 3. Time course for the changes in MPE, pCO2, pO2, and pH induced by intravenous administration of fentanyl at the doses indicated. At the time points outlined in the figure, tail-pinch testing and arterial blood samples were collected and analyzed as described under Materials and Methods.

Because the selective -opioid peptides (DPDPE and deltorphin II) and nonpeptide (BW373U86) agonists inhibited the hypercapnia induced by the continuous infusion of the selective µ-opioid analgesic alfentanil (Su et al., 1998), it has been proposed that -opioid receptor agonists mitigate the hypercapnia, resulting from narcotic analgesics. We investigated this possibility by measuring the effects of DPI-3290 on alfentanil-mediated hypercapnia and antinociception in rats. A2-µg/min intravenous infusion of alfentanil maintained full antinociception (MPE) and increased pCO₂ concentrations to 55 ± 8 mm/Hg in rats. These changes in tail-pinch latency (MPE) and pCO₂ induced by alfentanil reached steady state in 20 to 25 min and were maintained throughout the 60-min duration of this study (Fig. 4). Bolus intravenous doses of DPI-3290 that ranged from 0.2 to 1.0 mg/kg resulted in no change in tail-pinch latency (MPE) when coadministered during the alfentanil infusion. Bolus intravenous doses of DPI-3290 that ranged from 0.2 to 1.0 mg/kg reversed the alfentanil-induced elevation in pCO₂ by approximately 50% at all doses tested. Thirty minutes after the alfentanil infusion had been terminated, tail-pinch latency (MPE) and arterial blood gas (pCO₂) both returned to baseline values.

View larger version (22K): [in this window] [in a new window]   Fig. 4. Time course for effects of the mixed opioid agonist DPI-3290 on MPE and pCO2 responses in alfentanil-infused rats. Alfentanil was intravenously infused at 2 µg/kg/min. At the time points outlined in the figure, tail-pinch testing, and arterial blood samples were collected and analyzed as described under Materials and Methods.

The increases in antinociception (MPE) and arterial blood gas (pCO₂) induced by intravenous doses of DPI-3290, morphine, and fentanyl are illustrated in Fig. 5. As demonstrated in this figure, all three compounds are strong antinociceptive agents with varying potency: fentanyl > DPI-3290 » morphine. The most striking distinction between DPI-3290 and these compounds is the difference in the dose-response relationships that compare antinociception with hypercapnia.

View larger version (19K): [in this window] [in a new window]   Fig. 5. Dose-response relationship for antinociception (open symbols) and changes in pCO2 (closed symbols) for DPI-3290 (circles), morphine (squares), and fentanyl (triangles) in laboratory rats. Values represented are the mean ± S.E.M. of six separate experiments.

	Discussion

Top Abstract Materials and Methods Results Discussion References

 
DPI-3290 is a novel mixed opioid receptor agonist with potent antinociceptive activity (Gengo et al., 2003). Unlike morphine or fentanyl that demonstrate high-affinity binding and intrinsic activity at µ-opioid receptors (Wolozin and Pasternak, 1981; Alt et al., 2002), DPI-3290 has high-affinity binding and intrinsic activity at -, µ-, and -opioid receptors providing a new approach for managing the analgesic needs of patients with moderate-to-severe pain. The high-affinity binding and intrinsic activities of DPI-3290, morphine, and fentanyl at µ-opioid receptors provide an adequate explanation for their antinociceptive pharmacologies (Law and Loh, 1999). That is, by modulating the presynaptic release of neurotransmitters such as acetylcholine, norepinephrine, serotonin, dopamine, or substance P, they alter synaptic transmission (Childers, 1991; Satoh and Minami, 1995). These changes in neurotransmitter release have been linked to the actions of receptor-operated potassium channels, adenylate cyclase activity, and intracellular free ionized calcium concentrations (Schiller et al., 1992; Fan et al., 1993; Jin et al., 1994; Fan and Crain 1995). Together, these changes in neuronal signal transduction that are mediated by µ-opioid receptor agonists hyperpolarize the membrane potential, blunt voltage-sensitive calcium channel activity and dampen the cellular excitability of neurons, thus inhibiting painful stimuli.

Although the literature is replete with reports that describe how -opioid receptors agonists decrease the hypercapnic effects of µ-opioid agonists without changing their antinocicpetive actions (Rossi et al., 1994; Negri et al., 1995; O'Neill et al., 1997; Su et al., 1998; He and Lee, 1998), the molecular mechanism that underlies these effects is not fully elucidated. This would suggest that a compound with balanced agonist activity at - and µ-opioid receptors could have a pharmacological profile distinct from currently available narcotic analgesics. DPI-3290 is an agonist with high-affinity binding characteristics at opioid receptors that does not distinguish between the -, µ-, or -subtypes. This is in contrast to morphine or fentanyl, which are relatively selective agonists with high-affinity binding at the µ-subtype of the opioid receptor. If the mixed opioid receptor agoinst activity of DPI-3290 mitigates the hypercapnia associated µ-opioid receptor agonists, it might be anticipated that DPI-3290 would have strong antinociceptive action with reduced hypercapnia compared with morphine or fentanyl. Indeed, the 18.2-fold difference between the ED₅₀ value for changes in pCO₂ and the ED₅₀ value for antinociception elicited by DPI-3290 supports this hypothesis. These results with DPI-3290 can be contrasted with the 2.1-fold difference for morphine and the 3.7-fold difference with fentanyl, further supporting the concept that mixed opioid agonists are strong antinociceptive agents with less hypercapnia compared with selective µ-opioid receptor agonists such as morphine or fentanyl.

It is notable that high concentrations of DPI-3290, morphine, and fentanyl increase pCO₂ in laboratory animals. This is a characteristic of all opioid narcotic analgesics and has been purported to result from µ-opioid receptor activation. Inasmuch as the magnitude of changes in pCO₂ elicited by maximal tolerated doses of DPI-3290, morphine, and fentanyl were quantitatively similar, their relationship to the ED₅₀ value for antinociception was not. These findings further support the notion that mixed opioid receptor agonists such as DPI-3290 are potent antinociceptive agents that seem to act as competitive antagonists of the µ-opioid receptor mediated changes in pCO₂.

In the clinical setting, the most life-threatening adverse effect associated with the use of narcotic analgesics is respiratory depression. Today, all clinically available narcotic analgesics used to treat moderate-to-severe pain produce respiratory depression at therapeutic doses. Reports demonstrating cyclic D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH₂ blockade of antinociception and hypercapnia resulting from continuous alfentanil infusion argues that µ-opioid receptors underlie these effects. This would explain why therapeutic doses of narcotic analgesics are linked to respiratory depression. Reports that -opioid receptor agonists have no direct effect on respiration further support the notion that respiratory depression after morphine or fentanyl treatment is mediated by µ-opioid receptors. Although DPI-3290 is a potent µ-opioid receptor agonist, the difference in its effects on respiratory depression at comparable analgesic doses of morphine or fentanyl are likely to be valid. Not only were the effects of DPI-3290 on respiratory depression distinct from those measured with morphine or fentanyl but also DPI-3290 reversed the respiratory depression induced by continuous intravenous alfentanil infusion. Because DPI-3290 improved rather than added to the respiratory depression of alfentanil, this mixed opioid receptor agonist mitigates not only the respiratory depression coupled to its strong µ-opioid agonist activity but also the respiratory effects of narcotic analgesics such as alfentanil.

The characteristic that defines the paramount difference between DPI-3290 and narcotic analgesics such as morphine or fentanyl is the marked difference in the doses that elicit its antinociceptive and respiratory-depressant activities. Because the most life-threatening adverse effect associated with the use of narcotic analgesics for moderate-to-severe pain is respiratory depression, a drug with an appropriate separation between analgesia and hypercapnic activities could relieve severe pain with a broader therapeutic index. In this regard, the mixed opioid receptor agonist activity of DPI-3290 and its antinociceptive and hypercapnic pharmacologies is evidence that indicates the likelihood for achieving such a goal. Studies are underway to assess the efficacy and therapeutic index of DPI-3290 in more diverse models of pain and narcotic induced adverse effects and to determine its potential as an analgesic for the treatment of patients with moderate-to-severe pain.

	Footnotes

 
DOI: 10.1124/jpet.103.054429.

ABBREVIATIONS: DPI-3290, (+)-3-((-R)--((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide; BW373U86, (±)-4-((R*)--((2S*,5R*)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethylbenzamide; DPDPE, [D-Pen²,D-Pen⁵]-enkephalin; MPE, percent maximal possible effect.

Address correspondence to: Dr. Peter J. Gengo, Ardent Pharmaceuticals, Inc., 631 United Dr., Suite 200, Durham, NC 27713. E-mail: pgengo{at}ardentpharma.com

	References

Top Abstract Materials and Methods Results Discussion References

 

Alt A, Clark MJ, Woods JH, and Traynor JR (2002) Mu and delta opioid receptors active the same G-proteins in human neuroblastoma SH-SY5Y cells. Br J Pharmacol 135: 217–225.[CrossRef][Medline]

Chang K-J, Rigdon GC, Howard JL, and McNutt RW (1993) A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86. J Pharmacol Exp Ther 267: 852–857.[Abstract/Free Full Text]

Chang K-J (1984) Opioid receptors: multiplicity and sequelae of ligand-receptor interactions, in The Receptors (Conn M ed) pp 1–81, Academic Press, New York.

Childers SR (1991) Opioid receptor-coupled second messenger systems. Life Sci 48: 1991–2003.[CrossRef][Medline]

Clotz MA and Nahata MC (1991) Clinical uses of fentanyl, sufentanil and alfentanil. Clin Pharm 10: 581–593.[Medline]

Fan S and Crain SM (1995) Dual regulation by , µ and opioid receptor agonists of K⁺ conductance of DRG neurons and neuroblastoma x DRG neuron hybrid F11 cells. Brain Res 696: 97–105.[CrossRef][Medline]

Fan SF, Shen KF, and Crain SM (1993) µ and opioid agonists at low concentrations decrease voltage-dependent K currents in F11 neuroblastoma X DRG neuron hybrid cells via cholera toxin-sensitive receptors. Brain Res 605: 214–220.[CrossRef][Medline]

Gengo PJ, Pettit HO, O'Neill SJ, Wei K, McNutt R, and Chang K-J (2003) DPI-3290 [(+)-3-((-R)--((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl-N-(3-fluorophenyl)-N-methylbenzamide)]. I. A mixed opioid agonist with potent antinociceptive activity. J Pharmacol Exp Ther 307: 1221–1226.[Abstract/Free Full Text]

He L and Lee NM (1998) Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord. J Pharmcol Exp Ther 285: 1181–1186.[Abstract/Free Full Text]

Holder KA, Dougherty TB, and Chiang JS (1995) Postoperative pain management. Cancer Bulletin 47: 43–51.

Inturrisi CE (1990) Opiate analgesic therapy in cancer pain, in Advances in Pain Research and Therapy (Forley KM ed) vol. 16, pp. 133–154, Raven Press, New York.

Jin W, Lee NM, Loh HH, and Thayer SA (1994) Opioids mobilize calcium from inositol 1,4,5-triphosphate-sensitive stores in NG108-15 cells. J Neurosci 14: 1920–1929.[Abstract]

Law PY and Loh HH (1999) Regulation of opioid receptor activities. J Pharmacol Exp Ther 289: 607–624.[Abstract/Free Full Text]

Le Bars D, Gozariu M, and Cadden SW (2001) Animal models of nociception. Pharmacol Rev 53: 597–652.[Abstract/Free Full Text]

Lee PHK, McNutt RW, and Chang K-J (1993) A nonpeptidic delta opioid receptor agonist, BW373U86, attenuates the development and expression of morphine abstinence precipitated by naloxone in rat. J Pharmacol Exp Ther 267: 883–887.[Abstract/Free Full Text]

Mason P (1999) Central mechanism of pain modulation. Curr Opin Neurobiol 9: 436–441.[CrossRef][Medline]

McGilliard KL and Takemori AE (1978) Antagonism by naloxone of narcotic-induced respiratory depression and analgesia. J Pharmacol Exp Ther 207: 494–503.[Abstract/Free Full Text]

Negri L, Improta G, Lattanzi R, Potenza RL, Luchetti F, and Melchiorri P (1995) Interaction between the µ-agonist dermorphin and the -agonist [D-Ala₂,Glut₄] deltorphin in supraspinal antinociception and –opioid receptor binding. Br J Pharmacol 116: 2931–2938.[Medline]

O'Neill SJ, Collins MA, Pettit HO, McNutt RW, and Chang K-J (1997) Antagonistic modulation between the delta opioid agonist BW373U86 and the mu opioid agonist fentanyl in mice. J Pharmacol Exp Ther 282: 271–277.[Abstract/Free Full Text]

Reisine T and Pasternak G (1993) Opioid analgesics and antagonists, in The Pharmacological Basis of Therapeutics (Molinof PB and Ruddon RW eds) vol. 1, pp 521–555, MacMillan, New York.

Rossi GC, Pasternak GW, and Bodnar RJ (1994) µ and Opioid synergy between the periaqueductal gray and rotro-ventral medulla. Brain Res 665: 85–93.[CrossRef][Medline]

Satoh M and Minami M (1995) Molecular pharmacology of the opioid receptors. Pharmacol Ther 86: 343–364.

Schiller PW, Nguyen TMD, Weltrowska G, Wilkes BC, Lemieux C, and Chung NN (1992) Differential stereochemical requirements of µ vs opioid receptors for ligand binding and signal transduction: development of a class of potent and highly -selective peptide antagonists. Proc Natl Acad Sci USA 89: 11871–11875.[Abstract/Free Full Text]

Su YS, McNutt R, and Chang K-J (1998) Delta-opioid ligands reverse alfentanil-induced respiratory depression but not antinociception. J Pharmacol Exp Ther 287: 815–823.[Abstract/Free Full Text]

Wolozin BL and Pasternak GW (1981) Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc Natl Acad Sci USA 78: 6181–6185.[Abstract/Free Full Text]

Wong CL (1992) The effect of naloxone on restraint-induced antinociception in mice. Methods Find Exp Clin Pharmacol 14: 695–700.[Medline]

This article has been cited by other articles:

				A. Yassen, J. Kan, E. Olofsen, E. Suidgeest, A. Dahan, and M. Danhof Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory Depressant Effect of Norbuprenorphine in Rats J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 598 - 607. [Abstract] [Full Text] [PDF]

				J. D. S. Holt, M. J. Watson, J. P. Chang, S. J. O'Neill, K. Wei, W. Pendergast, P. J. Gengo, and K.-J. Chang DPI-221 [4-(({alpha}-S)-{alpha}-((2S,5R)-2,5-Dimethyl-4-(3-fluorobenzyl)-1-piperazinyl)benzyl)-N,N-diethylbenzamide]: A Novel Nonpeptide {delta} Receptor Agonist Producing Increased Micturition Interval in Normal Rats J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 601 - 608. [Abstract] [Full Text] [PDF]

				R. A. Roth, J. P. Luyendyk, J. F. Maddox, and P. E. Ganey Inflammation and Drug Idiosyncrasy--Is There a Connection? J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 1 - 8. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.103.054429v1 307/3/1227    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gengo, P. J. Articles by Chang, K.-J. Search for Related Content PubMed PubMed Citation Articles by Gengo, P. J. Articles by Chang, K.-J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ALFENTANIL CARBON DIOXIDE OXYGEN